Gregorio Barilà

INTRODUCTION The extensive use of lenalidomide (Len) in the first-line treatment of multiple myeloma (MM), either as post-autologous haematopoietic stem cell transplantation (AHSCT) maintenance or in combination with dexamethasone (RD) for transplant-ineligible patients, has resulted in an increased frequency of patients who have been exposed or, most importantly, are refractory to Len (Len-R) at first relapse.1, 2 Over the years, several combinations have been subsequently exploited for the...

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that supports the findings of this study are available in the of this article. Supporting Information Filename Description ejh70111-sup-0001-Tables.docxWord 2007 document , 31.8 KB Table S1: Comparisons of Pros and Cons of DWI-MRI and PET/CT techniques. Table S2A: Accuracy of advanced imaging tests for bone disease in PCD: umbrella analysis of published meta-analyses published since 2018.

Valentina Perrone,1 Gregorio Barilà,2 Luca Franceschini,3 Giuseppe Mele,4 Stefania Mazzoni,1 Maria Cappuccilli,1 Margherita Andretta,5 Marcello Bacca,6 Fausto Bartolini,7 Antonietta Barbieri,8 Alessandra Blasi,9 Alessandro Chinellato,10 Stefania Dell’Orco,11 Fulvio Ferrante,12 Renato Lombardi,13 Daniela Mancini,6 Romina Pagliaro,14 Arrigo Paciello,15 Maurizio Pastorello,16 Cataldo Procacci,17 Daniela Ricciardulli,14 Loredana Ubertazzo,18 Paola Valpondi,19 Alberto Zucchi,20 Luca Degli Esposti1...